Market Closed -
London S.E.
16:35:12 28/06/2024 BST
|
5-day change
|
1st Jan Change
|
44.5
GBX
|
+15.58%
|
|
+17.11%
|
-25.21%
|
Fiscal Period: Juni |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Capitalization
1 |
13.36
|
17.02
|
191.6
|
137.8
|
85.09
|
48.04
|
Enterprise Value (EV)
1 |
13.36
|
17.02
|
191.6
|
133.6
|
84.09
|
46.91
|
P/E ratio
|
-8.7
x
|
-17.5
x
|
-115
x
|
-63.3
x
|
-26.6
x
|
-7.95
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
437
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
426
x
|
EV / EBITDA
|
-
|
-
|
-
|
-51,815,193
x
|
-20,687,028
x
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-25,740,058
x
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-0%
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
61,427
|
64,835
|
66,657
|
68,069
|
68,069
|
107,946
|
Reference price
2 |
0.2175
|
0.2625
|
2.875
|
2.025
|
1.250
|
0.4450
|
Announcement Date
|
15/10/19
|
12/10/20
|
25/10/21
|
24/10/22
|
09/10/23
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
0.11
|
EBITDA
|
-
|
-
|
-
|
-2.578
|
-4.065
|
-
|
EBIT
1 |
-1.686
|
-
|
-1.718
|
-2.58
|
-4.066
|
-5.108
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-4,643.64%
|
Earnings before Tax (EBT)
1 |
-1.682
|
-
|
-1.718
|
-2.579
|
-4.025
|
-5.093
|
Net income
1 |
-1.452
|
-0.9859
|
-1.5
|
-2.172
|
-3.192
|
-4.093
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-3,720.91%
|
EPS
2 |
-0.0250
|
-0.0150
|
-0.0250
|
-0.0320
|
-0.0470
|
-0.0560
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-3.267
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
15/10/19
|
12/10/20
|
25/10/21
|
24/10/22
|
09/10/23
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
4.26
|
0.99
|
1.13
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-3.27
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-0.0300
|
-
|
-
|
Capex
1 |
-
|
-
|
-
|
-
|
-
|
0
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
0.91%
|
Announcement Date
|
15/10/19
|
12/10/20
|
25/10/21
|
24/10/22
|
09/10/23
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -25.21% | 60.71M | | +15.20% | 121B | | +19.67% | 113B | | +18.95% | 26.02B | | -23.86% | 19.39B | | -19.03% | 15.91B | | -20.90% | 15.09B | | -46.14% | 15.06B | | +63.85% | 14.93B | | +4.49% | 13.85B |
Bio Therapeutic Drugs
|